MyChesCo on MSN7d
ChromaTan and Landmark Bio Receive NIIMBL Grant to Advance AAV Gene Therapy Manufacturing
ChromaTan Inc. and Landmark Bio PBLLC have been awarded a grant from the National Institute for Innovation in Manufacturing ...
Technology Networks7d
Gene Therapy Offers Hope for Dravet Syndrome Treatment
Scientists developed a promising gene replacement therapy for Dravet syndrome in mice. The therapy alleviated symptoms ...
Evaluating DNA impurities in recombinant adeno-associated virus
A new study in the journal Human Gene Therapy indicates that DNA impurities derived from plasmid and host cell DNA are ...
GEN - Genetic Engineering and Biotechnology News8d
DMD Patient Dies After Treatment with Sarepta Gene Therapy
The patient, whom Sarepta described as a young man and later told news outlets was 16 years old, suffered acute liver failure ...
Breakthrough gene therapy alleviates Dravet syndrome symptoms in mice without side effects
In a groundbreaking advancement for families grappling with the challenges of Dravet syndrome, a rare and life-altering form ...
EurekAlert!8d
Breakthrough Dravet syndrome gene therapy in mice brings new hope to families
In a groundbreaking advancement for families grappling with the challenges of Dravet syndrome, a rare and life-altering form ...
The American Journal of Managed Care8d
Shaping Gene Therapy Approaches in Neuromuscular Disease
Adeno-associated virus (AAV)–mediated gene therapy was one of the focal points of this year's Muscular Dystrophy Association conference. Here, Barry Byrne, MD, PhD, University of Florida, speaks to ...
GlobalData on MSN12d
MeiraGTx and Hologen launch AI-backed gene therapy venture
Hologen has committed up to $430m in funding to support the development and commercialisation of AAV-GAD, MeiraGTx’s ...
Fierce Biotech13d
Hologen AI commits $430M to MeiraGTx Parkinson’s gene therapy
With MeiraGTx eyeing up how to take the drug through phase 3 and onto commercialization, Hologen has stepped in. The ...
MedCity News13d
Gene Therapy Biotech MeiraGTx Strikes Deal Bringing Generative AI to Pivotal Parkinson’s Trial
The Parkinson’s gene therapy, AAV-GAD, delivers the glutamic acid decarboxylase (GAD) gene into the subthalamic nucleus, a part of the brain key to motor control. It’s the same region targeted ...
LUXTURNA Continues to Lead in Retinal Gene Therapy with Increased Market Penetration | DelveInsight
DelveInsight's "LUXTURNA Market Size, Forecast, and Market Insight Report" highlights the details around LUXTURNA, a one-time ...
Taiwan News2d
SineuGene Therapeutics Announces FDA IND Clearance for SNUG01, a First-in-Class TRIM72-Targeted Gene Therapy for ALS
SineuGene Therapeutics Co., Ltd. ("SineuGene"), a clinical-stage biotech company pioneering innovative therapies for neurological disorders, today announced that the U.S. Food and Drug Administration ...